Oryzon Genomics S.A.
Madrid Stock ExchangeTotal Valuation
Oryzon Genomics S.A. carries a market capitalization of 232.77M, placing it among publicly traded companies globally. Its enterprise value stands at 219.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 232.77M |
| Enterprise Value | 219.28M |
Share Statistics
Oryzon Genomics S.A. currently has 77.51M shares outstanding.
| Shares Outstanding | 77.51M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | N/A |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2,015.02 |
Financial Position
Oryzon Genomics S.A. maintains a current ratio of 4.57, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.57 |
| Quick Ratio | N/A |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -45.84 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -1.60 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -4.35M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Oryzon Genomics S.A.'s stock has gained approximately 9.73978% over the past 52 weeks. The 50-day moving average sits at 2.98, while the 200-day moving average is 3.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9.73978% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.08 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.70M, while operating income came in at -14.70M.
| Revenue | N/A |
| Gross Profit | 7.73M |
| Operating Income | -14.70M |
| Pretax Income | -6.58M |
| Net Income | -2.23M |
| EBITDA | -14.70M |
| EBIT | -14.70M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
| Cash & Cash Equivalents | 25.42M |
| Total Debt | N/A |
| Net Debt | -25.42M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | N/A |
Scores
Oryzon Genomics S.A. posts an Altman Z-Score of 5.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.16 |